Novo Nordisk’s drug Saxenda is the latest to strike a shortage, as high need for weight loss medicines stimulates supply grabs throughout the market.
Saxenda will certainly have restricted schedule via completion of the year, according to a notification published Tuesday on a United States Food and also Drug Administration data source.
On a customer-facing web site for the drug, the firm claimed it is still making and also delivering Saxenda however alerted of problems loading prescriptions “for the remainder of 2023 and beyond.”
“We remain to see need for Saxenda rise at a considerable price, causing supply disruptions,“ a Novo speaker claimed in an e-mail.
Newer medicines from Novo Nordisk like Wegovy and also Ozempic, in addition to Eli Lilly & Co.’s diabetic issues drug Mounjaro, have actually ended up being extremely prominent in current months after researches revealed they can aid people shed loads of extra pounds. Only Wegovy is authorized by the FDA to deal with excessive weight.
While Saxenda functions in a similar way to these brand-new medicines, it’s much less efficient and also aids people shed much less weight. Recent scarcities of Wegovy and also Mounjaro, nonetheless, have actually caused restored passion. Prescriptions for Saxenda leapt virtually 30,000 in between May 2023 and also June 2023, according to Bloomberg Intelligence information, the most significant regular monthly dive over the previous 2 years.
On a Novo web site for Wegovy, the firm alerts possible people versus changing to Saxenda, claiming “we cannot guarantee supply to match the continuous rising demand for weight management medications.”